Reverse Regulation of Endothelial Cells and Myointimal Hyperplasia on Cell Proliferation by a Heatshock Protein-Coinducer After Hypoxia
arly restenosis (6 to 12 months after intervention) resulting from myointimal hyperplasia (MIH) is related to upstream proliferation of SMCs and down-regulated endothelial function that may be related to clinical symptoms. Therefore, strategies have been proposed to prevent early restenosis by agents and newly carotid artery stenting. Recently, drug-eluting stents is an alternative therapy still with problems.
Iroxanadine (Cytrx; 5, 6-dihydro-5-(1-piperidinyl) methyl-3-(3-pyridil)-4H-1, 2, 4-oxadiazine), originally synthesized by Biorex-Hungary (BRX-235), is a drug candidate with a marked cytoprotection by heatshock protein (HSP)-coinduction. 1 This molecule has been proposed to stimulate the migration of ECs via p38 stress-activated-protein-kinase (SAPK) and enhanced expression of HSPs and heat-shock transcription factor 1. 1 However, no data were published according to this HSPcoinducer focusing on the effect regarding MIH.
We will show how BRX-235 interferes with MIH, human brain endothelial cells (HBEC) and vascular smooth muscle cells (VSMC) under hypoxia/reoxigenation.
Methods
The following cells were isolated from human origin: VSMCs/ carotid wall 2 ; brain capillary endothelial cells (HBEC)/cut of brain gray matter 3 from accidental cadaver donors, and MIH-cells/segment of operated artery.
Cultivated cells were exposed to hypoxia (for 1 hour) in BillupsRothenberg chamber and reoxygenated for overnight. Before hypoxia the endothelial cells were starved overnight by serum deprivation (1%).
MIH cells were isolated and cultured from surgical speciments of early restenosis. The 7 patients (age 62 to 78) were operated (6 to 12 months) after the first endarteriectomy, whereas the second interventions were patch plastic, or interposition. No patients were lost and no neurological events occurred because of surgery.
Permission to isolate cells of human origin was granted by the Ethical Committee of the Hungarian Ministry of Health (595/98/KO and 73/1998/ETT). Materials were obtained primarily from Sigma.
Cell cultures were treated with HSP-coinducer (10 Ϫ8 -10 Statistical analyses were performed by 1-way ANOVA and significance calculated by Student t test.
Results
The proliferation rate of nonpathological cells: VSMC (nϭ4) and HBECs (nϭ6) decreased (21.2%, Pϭ0.049, and 30.7%, Pϭ0.009) after hypoxia/reoxygenation. Conversely, the activity of cultured MIH (nϭ7) cells increased (31.4%, Pϭ0.001; Figure  1a ). Using HSP-coinducer at normoxia, the upregulated proliferation rate of MIH-cells reduced (22.8Ϯ1.1 Pϭ0.048) similarly after hypoxia/reoxygenation (0.1 mol/L to 1 mol/L Iroxanadine 37.1Ϯ2.5% Pϭ0.007, 34.3Ϯ3.0% Pϭ0.009; Figure 1b) . Contrarily, the downstreamed proliferation rate of HBECs was upregulated while the test drug did not elicit any effect on VSMC (Figure 1c) .
In MIH cell population the subpopulation of G0/G1 phase cells represented the highest percentage, but no change was observed after HSP-coinduction. The number of S phases of cells downstreamed (17.8Ϯ0.7/12.3Ϯ1.0%; Pϭ0.008) and G2/M increased (10.2Ϯ1.1/17.0Ϯ0.9%; Pϭ0.0078; Figure  2a, b ). An opposite effect appeared by SAPK p38 inhibitor (SB203580 1 mol/L). The number of S phase cells increased (17.0Ϯ0.9 /21.2Ϯ1.0%; Pϭ0.046) except for G2/M subpopulation (8.2Ϯ0.8 /9.8Ϯ1.0%; Figure 2a) . The HSP-coinducer (1 mol/L) counteracted the effect of SB203580 (1 mol/L) and increased the cell ratio of G2/M phase and decreased the upregulated cell ratio of S phase (Figure 2b) . Thus, the HSP-coinducer induced p38-dependent cell cycle redistribution on cell subpopulations.
In VSMC after hypoxia/reoxygenation, HSP72 and CDKN1A mRNA levels did not change (data not depicted). In HBEC treated with HSP-coinducer (for 5 days) after hypoxia/ reoxigenation both the HSP72 mRNA (4.9-fold) and the CDKN1A mRNA (4.7-fold) decreased. In MIH a slight upregulation of HSP72 (2.6-to 3.0-fold) and CDKN1A mRNA level (1.5-to 1.9-fold) was measured. The HSP-coinducer treatment reversed the effect of hypoxia/reoxygenation (Figure 3) . 
Discussion
A definitive therapy on restenosis and in-stent stenosis, especially targeting VSMC as well as endothelial cell dysfunction, is warranted. 4 Cultured MIH-cells with hypoxia/reoxygenation are used as model of restenosis to test drug actions. In between MIH-cells and endothelial cells reverse regulation was observed on cell proliferation particularly after hypoxia. The proliferation of nonpathological cells (VSMC and EC) decreased while pathological MIH-cells greatly increased. This novel observation explains different mechanisms in early restenosis.
Drug-induced HSPs may have therapeutic effects under different pathological conditions. 1 After treatment by HSPcoinducer, the augmented proliferation of MIH-cells decreased but the proliferation of deregulated EC cells was enhanced. Simultaneously, the expression of HSP72 and CDKN1A are upregulated in agreement with clinical reports where compromised endothelial cell proliferation and upregulated HSP72 expression was described in VSMC after transluminal balloon angioplasty. 5 MIH-cells are characterized by augmented proliferation, similar to tumor cells. Induced by heat or stress proteins, tumor suppressor p53 inhibited cell growth by enhanced expression of CDKN1A/p21. 6 While not in HBEC and VSMCs, CDKN1A/p21 upregulation was documented in the MIH cell culture after HSP-induction.
As we documented, MIH and endothelial cells, the 2 key players of early restenosis, were oppositely regulated. Iroxanadine, a HSP-coinducer, may prevent restenosis by its regulatory action. 
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